Project Mountain - Comparing SpO2 and SaO2 for Accuracy

Last updated: April 1, 2025
Sponsor: Philips Clinical & Medical Affairs Global
Overall Status: Active - Recruiting

Phase

N/A

Condition

Low Blood Pressure (Hypotension)

Treatment

SaO2 Sampling

Clinical Study ID

NCT06372106
MA_PM_Mountain_2022_11496
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

The main goal of this study is to look at the performance of the neonatal, infant, and pediatric Philips SpO2 sensors with the Philips FAST Pulse Oximetry technology. Oxygen saturation measurements (SpO2) will be obtained via pulse oximetry and invasive arterial oxygen measurements (SaO2) will be obtained via arterial blood samples as part of your clinical care and assessed by co-oximetry. The study will aim to enroll a diverse population to help us understand the impact of skin pigmentation.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Subject aged 18 years or older or parent/legal guardian of subject aged less than 18years, willing and able to understand and provide written informed consent/assent.

  • Weight and/or age within intended use of at least one SpO2 sensor under test at timeof enrollment.

  • Willing and able to wear study devices in addition to SoC devices and during SoCprocedures.

  • In-patient within a neonatal or pediatric intensive care unit (e.g. NICU, PICU,PCICU).

  • Has arterial access and ability to have arterial blood samples drawn as part oftheir SoC and analyzed by CO-Oximetry.

Exclusion

Exclusion Criteria:

  • Known pregnancy or lactating females (self-reported)

  • Injury, wounds, physical malformation, hyperkeratosis, or compromised/non-intactskin at sensor application site (i.e. fingers, toes, hands, feet, ears, nasal ala).Note: Certain malformations may be allowed if determined it would not affectapplication of sensor with the pulse oximetry system.

  • Self-reported severe contact allergies to standard adhesives or other materialsfound in pulse oximetry sensors. Note: Subject may be considered eligible if subjectcan wear non-adhesive sensor.

  • Unwillingness or inability to remove nail polish or artificial nails from sensorapplication site.

  • Nail fungus on sensor application site.

  • Wearing and unable to remove jewelry from sensor application site.

  • Dye injection within 48 hours of enrollment.

  • Known dysfunctional hemoglobin levels (COHb >3%, MetHb >2%, and ctHb <10g/dl)

  • Undergoing phototherapy for neonatal hyperbilirubinemia during arterial bloodsampling

Study Design

Total Participants: 560
Treatment Group(s): 1
Primary Treatment: SaO2 Sampling
Phase:
Study Start date:
April 04, 2024
Estimated Completion Date:
December 31, 2025

Study Description

This is a prospective, multi-center, multi-phase, unblinded, non-randomized. self-controlled, observational study. All data analyses specified below will be calculated and summarized by each of SpO2 sensors under test. Demographics and baseline characteristics, including sex assigned at birth, age, ethnicity, race, baseline height, baseline weight, BMI, skin pigmentation and sensor application site measurements will be summarized with descriptive statistics using the analysis set.

Connect with a study center

  • Phoenix Children's

    Phoenix, Arizona 85016
    United States

    Active - Recruiting

  • University of Nebraska Medical Center

    Omaha, Nebraska 68114
    United States

    Active - Recruiting

  • Duke University Medical Center

    Durham, North Carolina 27710
    United States

    Active - Recruiting

  • Medical University of South Carolina

    Charleston, South Carolina 29425
    United States

    Active - Recruiting

  • Baylor College of Medicine

    Houston, Texas 77030
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.